Equillium Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Equillium şirketinin kazançlarının yıllık 28.2% oranında düşmesi, yıllık gelirinin ise yıllık 8.3% oranında artması bekleniyor. EPS'nin yıllık 15.5% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-28.2%

Kazanç büyüme oranı

-15.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	8.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:0FY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	13	-36	-27	-27	2
12/31/2025	N/A	-39	-26	-26	4
12/31/2024	37	-14	-8	-15	2
9/30/2024	46	-5	-22	-21	N/A
6/30/2024	43	-8	-16	-16	N/A
3/31/2024	38	-12	-23	-23	N/A
12/31/2023	36	-13	-22	-22	N/A
9/30/2023	43	-8	12	12	N/A
6/30/2023	34	-18	0	0	N/A
3/31/2023	25	-29	-5	-5	N/A
12/31/2022	16	-62	-9	-9	N/A
9/30/2022	N/A	-76	-47	-47	N/A
6/30/2022	N/A	-72	-41	-41	N/A
3/31/2022	N/A	-67	-37	-36	N/A
12/31/2021	N/A	-39	-32	-32	N/A
9/30/2021	N/A	-37	-30	-30	N/A
6/30/2021	N/A	-34	-28	-28	N/A
3/31/2021	N/A	-31	-26	-26	N/A
12/31/2020	N/A	-30	-25	-25	N/A
9/30/2020	N/A	-28	-26	-25	N/A
6/30/2020	N/A	-28	-25	-25	N/A
3/31/2020	N/A	-27	-25	-25	N/A
12/31/2019	N/A	-26	-23	-23	N/A
9/30/2019	N/A	-23	-18	-18	N/A
6/30/2019	N/A	-22	-15	-15	N/A
3/31/2019	N/A	-18	-11	-11	N/A
12/31/2018	N/A	-13	-8	-8	N/A
9/30/2018	N/A	-10	-4	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0FY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 0FY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 0FY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 0FY şirketinin gelirinin (yıllık 8.3% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0FY şirketinin gelirinin (yıllık 8.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0FY 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Equillium Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

New major risk - Financial position

Forecast to breakeven in 2024

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

New minor risk - Profitability

Forecast to breakeven in 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New major risk - Share price stability

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

High number of new directors

High number of new directors

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

New 90-day high: €6.40

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

New 90-day low: €4.06

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Equillium, Inc. Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis

Equillium, Inc. Announces Executive Changes

Equillium, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin